NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $112.56 -2.55 (-2.22 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$111.08Now: $112.56▼$114.9250-Day Range$115.11MA: $126.17▼$135.1552-Week Range$72.14Now: $112.56▼$136.26Volume880,688 shsAverage Volume743,202 shsMarket Capitalization$10.50 billionP/E Ratio53.35Dividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $137.39, Neurocrine Biosciences has a potential upside of 22.1% from its current price of $112.56.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.6 Community Rank Outperform VotesNeurocrine Biosciences has received 878 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeurocrine Biosciences has received 331 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeurocrine Biosciences has received 72.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote “Outperform” if you believe NBIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,221,844.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions96.93% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 116.45% in the coming year, from $2.31 to $5.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 53.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 53.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 16.12.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 16.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.96 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX Previous Symbol CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone858-617-7600Debt Debt-to-Equity Ratio0.10 Current Ratio2.00 Quick Ratio1.96Price-To-Earnings Trailing P/E Ratio53.35 Forward P/E Ratio48.73 P/E GrowthN/A Sales & Book Value Annual Sales$788.10 million Price / Sales13.32 Cash Flow$0.67 per share Price / Cash Flow168.81 Book Value$6.92 per share Price / Book16.27Profitability EPS (Most Recent Fiscal Year)$0.39 Net Income$37.01 million Net Margins20.36% Return on Equity39.22% Return on Assets20.06%Miscellaneous Employees585 Outstanding Shares93,250,000Market Cap$10.50 billion Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $112.56 -2.55 (-2.22 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NBIX News and Ratings via Email Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)? Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBIX shares have increased by 31.0% and is now trading at $112.56. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences. When is Neurocrine Biosciences' next earnings date? Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Neurocrine Biosciences. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Monday, August, 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.16. The firm earned $302.40 million during the quarter, compared to the consensus estimate of $261.66 million. Neurocrine Biosciences had a return on equity of 39.22% and a net margin of 20.36%. The business's revenue for the quarter was up 64.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.71 earnings per share. View Neurocrine Biosciences' earnings history. What price target have analysts set for NBIX? 19 equities research analysts have issued twelve-month target prices for Neurocrine Biosciences' shares. Their forecasts range from $108.00 to $161.00. On average, they expect Neurocrine Biosciences' stock price to reach $137.39 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View analysts' price targets for Neurocrine Biosciences. Has Neurocrine Biosciences been receiving favorable news coverage? News stories about NBIX stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neurocrine Biosciences earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news about Neurocrine Biosciences. Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Gilead Sciences (GILD), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), salesforce.com (CRM), Trade Desk (TTD) and Square (SQ). Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the following people: Dr. Kevin C. Gorman, CEO & Director (Age 61)Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62) What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Mint Tower Capital Management B.V. (8.04%), First Trust Advisors LP (0.92%), Victory Capital Management Inc. (0.69%), Sumitomo Mitsui Trust Holdings Inc. (0.46%), GW&K Investment Management LLC (0.40%) and Swiss National Bank (0.37%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences. Which institutional investors are selling Neurocrine Biosciences stock? NBIX stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, Rhenman & Partners Asset Management AB, Jennison Associates LLC, Candriam Luxembourg S.C.A., UBS Group AG, Russell Investments Group Ltd., and Mutual of America Capital Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin. View insider buying and selling activity for Neurocrine Biosciences. Which institutional investors are buying Neurocrine Biosciences stock? NBIX stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Scout Investments Inc., Kornitzer Capital Management Inc. KS, Victory Capital Management Inc., State of Alaska Department of Revenue, Frontier Capital Management Co. LLC, Premier Asset Management LLC, and Assenagon Asset Management S.A.. View insider buying and selling activity for Neurocrine Biosciences. How do I buy shares of Neurocrine Biosciences? Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $112.56. How big of a company is Neurocrine Biosciences? Neurocrine Biosciences has a market capitalization of $10.50 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe. What is Neurocrine Biosciences' official website? The official website for Neurocrine Biosciences is www.neurocrine.com. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
